Cvergenx has developed an informatics-based approach to radiation treatment planning that enables radiation oncologists to personalize and optimize radiation therapy.
The company’s Precision Genomic Radiation Therapy platform (pGRT™) takes a mathematical, rather than empirical, approach to the integration of genomics into radiation treatment and planning. This unique application of medical mathematics is central to the Cvergenx patented Radiosensitivity Index (RSI) and Genomic Adjusted Radiation Dose (GARD). Combined, these parameters provide the first opportunity to adapt radiation treatment and dose to improve outcomes on a patient-by-patient basis.
We are now in the process of demonstrating how patients can benefit by integrating biological information into radiotherapy treatment plans to optimize dose on an individualized basis.
The sequencing of the human genome has revealed that cancer is not a single disease but multiple diseases that are inherently different at the genetic level. This realization has led to the era of precision medicine.
News & Publications
"We are focused on delivering a genomic framework for personalized medicine using biological information to inform the radiation treatment parameters. This technology allows us to predict which patients benefit from radiation more than others allowing for the personalization of radiation therapy."
— Javier Torres-Roca, MD
PRESS RELEASES >
Cvergenx and HCG Partner to Launch Genomic Radiation Therapy in India & Africa
Business Wire, December 19, 2017
TAMPA, FL & BENGALURU, India — Cvergenx, Inc. and Healthcare Global Enterprises, Ltd. (NSE:HCG) today announced an exclusive collaboration to develop, validate and commercialize precision genomic radiation therapy (pGRTTM) technology in India and Africa. This joint venture between HCG and Cvergenx will be the exclusive vehicle through which pGRT will be made available in those countries. READ FULL PRESS RELEASE →
Moffitt Cancer Center & Cvergenx Partner to Personalize Radiation Therapy
August 9, 2017
Tampa, FL — Moffitt Cancer Center and Cvergenx announced a new research partnership that aims to revolutionize radiation therapy. The goal of the Future of Radiation Therapy (FORT) project is to create a framework for using a patient’s genetic information to provide a personalized radiation treatment plan. READ FULL PRESS RELEASE →
A Tailored Approach to Cancer Treatment
Tampa Bay Times, August 18, 2017
Tampa, FL — Treatment at Moffitt Cancer Center has been more precise since doctors and researchers there began using targeted drug therapies nearly a decade ago. And soon they plan to expand on that approach, known as personalized medicine, to include radiation therapy. READ FULL PRESS RELEASE →
Cvergenx, Inc. Brings Radiation Oncology into the Era of Individualized Medicine
January 4th, 2017
Tampa, FL — In an endeavor to bring radiation oncology into the era of individualized medicine, Cvergenx, Inc. today reaffirmed its plans to commercialize the first genomics-driven approach to precision radiation therapy. This advance, recently recognized by The Lancet Oncology, one the most widely read and well respected peer-reviewed oncology journals in the world today, was echoed in an editorial commentary in the same publication. READ FULL PRESS RELEASE →
for Radiation Dosage
The Lancet Oncology podcast, February 1, 2017
Javier Torres-Roca, MD and Louis B. Harrison, MD discuss genome-based modeling and its uses in calculating the appropriate radiation dosage.
The Lancet Oncology, Volume 18, Number 2, February 2017
The Lancet Oncology, Volume 18, Number 5, May 2017
The Lancet Oncology, Volume 18, Number 2, February 2017
International Journal of Radiation Oncology, Volume 98, Number 5, August 2017
JAMA Oncology, June 2017
International Journal of Radiation Oncology, Volume 92, Number 4, April 2015
Translational Cancer Research, Volume 6 Supplement 2, March 2017
The vision and mission of Cvergenx is to bring precision medicine to radiation oncology by enabling clinicians to personalize and optimize radiation therapy dose to match an individual’s biology and genetic differences.
Cvergenx is led by an experienced team of highly trained clinicians, biostatisticians and business professionals with a deep understanding of radiation oncology, genomics, bioinformatics and technology commercialization.
Raymond F. Vennare
Raymond F. Vennare (Chairman & CEO) is an accomplished senior executive and biotechnology entrepreneur with a long history of founding, launching and leading companies ranging from bioinformatics, diagnostics and therapeutic drug delivery to FDA-cleared medical devices. In addition to advising nationally ranked universities, philanthropic organizations and multi-national publicly traded companies, Raymond is past co-founder and CEO of Thermal Therapeutic Systems, President and Chief Executive Officer of ImmunoSite, Senior Vice President and Chief Information Officer of TissueInformatics and President of VSinteractive.
Javier F. Torres-Roca, MD
Javier F. Torres-Roca, MD (Co-founder & Chief Medical Advisor) is Director of Clinical Research in the Department of Radiation Oncology at Moffitt Cancer Center and clinical faculty with a sub-specialty in urological and cutaneous malignancies. Javier earned his medical degree from the University of Puerto Rico followed by post-doctoral training in immunology and molecular biology with Nobel Laureate Professor Luc Montagnier (Institute Pasteur) and Drs. Irving Weismann and Leonard Herzenberg (Stanford). He completed his clinical training in radiation oncology at the University of California and is an ABR board certified radiation oncologist.
Steven A. Eschrich, PhD
Steven A. Eschrich, PhD (Co-founder & CSO) is Senior Member at the H. Lee Moffitt Cancer Center and Research Institute in the Department of Biostatistics and Bioinformatics, Scientific Director of the Moffitt Cancer Center Cancer Informatics Core Facility and Associate Professor of Oncologic Sciences at the University of South Florida. Dr. Eschrich received his Ph.D. from the University of South Florida with an emphasis on developing scalable machine learning algorithms for bioinformatics applications including extensive experience in gene expression microarray analysis in translational cancer research.
John G. Kokales, MD
John G. Kokales, MD, (Board Director) is a former practicing physician, Senior Medical Director for Medicare and Medical Director for UPMC Health Plan. John chaired the Pharmacy & Therapeutics Committee, co-chaired the Quality Committee for the CMI physician network and chaired the Clinical Pathways Committee at Shadyside Hospital. He is past Member of the Physicians Advisory Committee of the CMI, the Critical Clinical Information Task Force for Cerner Electronic medical record implementation, the Physician Advisory Committee Cerner Hospital implementation and Institutional Review Board at UPMC Shadyside.
Pamela A. Bush, PhD/MBA
Pamela A. Bush, PhD/MBA (Board Director) is the former Director of Corporate Business Development at Eli Lilly & Company where she was lead negotiator for term sheets and contracts to in-license and out-license strategic assets. Before becoming Director or Corporate Business Development, Pamela served as manager in R&D Finance at Lilly and served as Director of Investment Programs for the Pittsburgh Life Sciences Greenhouse in Pittsburgh, PA. Pamela holds a PhD from Carnegie Mellon University, College of Science, and MBA from the Carnegie Mellon University, Tepper School of Business.
David S. Smith, JD
David S. Smith, JD (Board Director) a corporate lawyer focusing on intellectual property transactions, venture financings and regulatory matters for life sciences companies and investors, is of counsel with Pepper Hamilton LLP, and a member of the firm's Health Sciences Department. David is active in a number of trade organizations and serves on the executive committee of Tissue Engineering and Regenerative Medicine International Society. He is a past member of the board of directors of the Pennsylvania Biotechnology Association and secretary of the Pittsburgh Tissue Engineering Initiative.
The Radio Sensitivity Index (RSI) was developed as an objective measure of tumor intrinsic radiosensitivity and Genomic Adjusted Radiation Dose (GARD) was developed to optimize radiation therapy dose based upon the biological differences across tumors.
If you would like more information about the company, our expertise or the pGRT technology platform, please don’t hesitate to contact us directly. We respect your privacy and treat all electronic communication as personal, proprietary and confidential.